Review
Copyright ©The Author(s) 2018.
World J Hepatol. Feb 27, 2018; 10(2): 186-212
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186
Table 3 Selected directly acting antiviral agents and host targeting agents in the pipeline[63]
Drugs nameCompanyTarget/active sitePhase
NS3/4A protease inhibitors
Vaniprevir (MK-7009)MerckActive site/macrocyclicIII
Voxilaprevir GS-9857GileadActive siteIII
Glecaprevir (ABT-493)AbbvieActive siteIII
IDX21437IdenixActive siteII
Sovaprevir (ACH-1625)AchillionActive site/macrocyclic?II
Nucleoside analog NS5B polymerase inhibitors (NI)
MK-3682 (formerly IDX20963)MerckActive siteII
ACH-3422Achillion/JanssenActive siteII
Non- Nucleoside analog NS5B polymerase inhibitors (NNI)
Beclabuvir (BMS-791325)Bristol-Myers SquibNNI site 1/Thumb 1III
Setrobuvir (ANA598)Anadys/RocheNNI site 4?/palm 1II
NS5A inhibitors
BMS-824393Bristol-Myers SquibbNS5A proteinII
PPI-461PresidioNS5A proteinII
PPI-668PresidioNS5A proteinII
Pibrentasvir (ABT-530)AbbvieNS5A proteinIII
ACH-2928AchillionNS5A proteinI
Ruzasvir (MK-8408)MerckNS5A proteinII
Host targeting agents
SCY-635ScynexisCyclophilin inhibitorII
MiravirsenSantarismiRNA122 antisense NAII
RG-101-RegulusmiRNA122 antisense NAII
TT-0034Tacere TherapeuticsRNA interference with HCVII